These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25906751)

  • 1. Loss of Wave1 gene defines a subtype of lethal prostate cancer.
    Sowalsky AG; Sager R; Schaefer RJ; Bratslavsky G; Pandolfi PP; Balk SP; Kotula L
    Oncotarget; 2015 May; 6(14):12383-91. PubMed ID: 25906751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular pathology of prostate cancer].
    Tímár J
    Magy Onkol; 2019 Mar; 63(1):5-9. PubMed ID: 30889615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular biology of prostate cancer: current understanding and clinical implications.
    Gandhi J; Afridi A; Vatsia S; Joshi G; Joshi G; Kaplan SA; Smith NL; Khan SA
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):22-36. PubMed ID: 29282359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.
    Zhou J; Ning Z; Wang B; Yun EJ; Zhang T; Pong RC; Fazli L; Gleave M; Zeng J; Fan J; Wang X; Li L; Hsieh JT; He D; Wu K
    Cell Death Dis; 2015 Oct; 6(10):e1955. PubMed ID: 26512963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
    Katzenwadel A; Wolf P
    Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving resistance specificity in prostate cancer.
    Wadhwa B; Dumbre R
    Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of castration-resistant prostate cancer translational research].
    Maeno A; Habuchi T
    Nihon Rinsho; 2016 Jan; 74(1):40-4. PubMed ID: 26793877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.